HC Wainwright started coverage on shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat reports. The firm issued a buy rating on the stock. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ Q3 2026 earnings at ($1.85) EPS, Q4 2026 earnings at ($1.44) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.29) EPS and FY2029 earnings at ($1.59) EPS.
Other analysts have also recently issued reports about the company. Weiss Ratings raised Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Wall Street Zen raised Lakewood-Amedex Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Lakewood-Amedex Biotherapeutics presently has an average rating of “Hold”.
Get Our Latest Stock Analysis on Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics Trading Down 15.7%
Shares of Lakewood-Amedex Biotherapeutics stock opened at $0.20 on Wednesday. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.20 and a 52-week high of $98.20. The business’s 50-day moving average price is $1.39. The firm has a market capitalization of $474,000.00 and a price-to-earnings ratio of -0.04.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter. Equities analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current fiscal year.
Lakewood-Amedex Biotherapeutics Company Profile
Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.
The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.
Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.
Featured Articles
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
